TY - JOUR
T1 - Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. the ELATED-2 Pilot Trial
AU - Cassano, Paolo
AU - Petrie, Samuel R.
AU - Mischoulon, David
AU - Cusin, Cristina
AU - Katnani, Husam
AU - Yeung, Albert
AU - De Taboada, Luis
AU - Archibald, Abigal
AU - Bui, Eric
AU - Baer, Lee
AU - Chang, Trina
AU - Chen, Justin
AU - Pedrelli, Paola
AU - Fisher, Lauren
AU - Farabaugh, Amy
AU - Hamblin, Michael R.
AU - Alpert, Jonathan E.
AU - Fava, Maurizio
AU - Iosifescu, Dan V.
N1 - Funding Information:
Manuscript received September 6, 2006; revised December 12, 2006. This work was supported by the National Technology Agency of Finland (TEKES). This paper was recommended by Associate Editor E. A. B. da Silva. H. Olkkonen is with the Department of Physics, University of Kuopio, 70211 Kuopio, Finland (e-mail: hannu.olkkonen@uku.fi). J. T. Olkkonen is with the VTT Technical Research Centre of Finland, 90571, Oulu, Finland (e-mail: juuso.olkkonen@vtt.fi). Digital Object Identifier 10.1109/TCSII.2007.895327
Publisher Copyright:
© Copyright 2018, Mary Ann Liebert, Inc., publishers 2018.
PY - 2018/12
Y1 - 2018/12
N2 - Objective: Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD). Background: T-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress. Materials and methods: We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D 17 ) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm 2 ; 36.2 mW/cm 2 ; up to 65.2 J/cm 2 ; 20-30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed. Results: The effect size for the antidepressant effect of t-PBM, based on change in HAM-D 17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events. Conclusions: T-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.
AB - Objective: Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD). Background: T-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress. Materials and methods: We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D 17 ) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm 2 ; 36.2 mW/cm 2 ; up to 65.2 J/cm 2 ; 20-30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed. Results: The effect size for the antidepressant effect of t-PBM, based on change in HAM-D 17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events. Conclusions: T-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.
KW - depression
KW - low-level laser therapy
KW - randomized controlled trial
UR - http://www.scopus.com/inward/record.url?scp=85053529628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053529628&partnerID=8YFLogxK
U2 - 10.1089/pho.2018.4490
DO - 10.1089/pho.2018.4490
M3 - Article
AN - SCOPUS:85053529628
VL - 36
SP - 634
EP - 646
JO - Journal of Clinical Laser Medicine and Surgery
JF - Journal of Clinical Laser Medicine and Surgery
SN - 1549-5418
IS - 12
ER -